BioSpace News Archive

IPO Initial Public Offering finance business concept. 3D render vector illustration of Trading on IPO Initial Public Offering, Business Startup and Stock Market Concept. Public offering share launch

IPO tracker

Cardio biotech Kardigan binds off $400M upsized IPO

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.

June 18, 2026

·

16 min read

·

Editorial Team

Illustration of businessman with a telescope in a boat, looking for something

Job Trends

On the chopping block? When layoffs may and may not lurk around the corner

Cost cutting is just one factor driving biopharmas to whittle away at their workforces. An analyst discusses more common reasons layoffs occur and which employees are most at risk.

June 18, 2026

·

3 min read

·

Angela Gabriel

Magnifying glass focusing on target among icons of humans

Opinion

Convert nonresponder insights into smarter drug development strategies in immunology

While agents like AbbVie’s Humira have transformed the treatment landscape, not all patients benefit equally from the drug. Better biomarker analysis and more investment in mechanistic trials can inform the development of more effective therapies with broader clinical value.

June 18, 2026

·

5 min read

·

Kori Wallace

Illustration showing candidate resume being reviewed by employer

Job Trends

Ones to watch: 4 biotechs with recent Series B raises (that are also hiring)

Biopharmas that announced Series B financing this year and are looking for employees as they grow include two companies that received $100 million or more. One has partnerships with three Big Pharmas.

June 18, 2026

·

4 min read

·

Angela Gabriel

Press Releases

Laprophan Completes the Acquisition of Rivopharm, Accelerating Its International Expansion Strategy

June 18, 2026

·

6 min read

Press Releases

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)